J Thromb Haemost: Recurrent thrombosis in patients with antiphospholipid-positive venous or arterial thrombosis

Patients with positive antiphospholipid antibodies (aPL) and thromboembolism (TE) are at risk of TE recurrenceHowever, few studies have been able to distinguish patients from initial eventsrecently published a study in journal Sthrombosis and Haemostasis, an authoritative journal of thrombosis and clotting disease, in which researchers conducted a systematic review and meta-analysis to investigate patients with aPL-positive venous TE (VTE) as well as arterial TE (ATE) patientsThe researchers searched the PubMed, CINAHL, Cochrane and EMBASE databasesThe criteria for selection were prospective trials or cohort studies in aPL-positive ATE patients or VTE patientsExclude studies of patients who do not provide an estimated recurrence rate, whether the unspecified event is ATE or VTE, including multiple events, or 10 patientsThe researchers used a random effect model to estimate the two-year aggregate ratio10 studies describing Patients with VTE, two at-an cases of ATE and 5 cases of VTE or ATE patientsIn VTE patients treated with anticoagulant treatment, the two-year recurrence rate of TE was 0.054 (95% confidence interval: 0.037, 0.079), and the two-year ratio of patients who did not receive anticoagulant therapy was 0.178 (95% CI: 0.150, 0.209)Most studies do not distinguish between induced or uninduced VTEThe proportion of TE recurrences in two years in ATE patients treated with anticoagulant treatment was 0.220 (95% CI: 0.149, 0.311);aPL-positive ATE patients may benefit from different anti-thrombotic methods compared to aPL-positive VTE patientsIn order to determine the best antithrombotic strategy, a forward-looking study of te queues with well-defined aPL-positive results must be carried out